Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)

ClinicalTrials.gov ID: NCT07936266

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07936266. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Open-label, Multicenter Trial of Asciminib (ABL001) Added to Inotuzumab Ozogamicin (Besponsa®) in Patients With Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.

Study identification

NCT ID: NCT07936266
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Sunil G. Iyer; Other
Enrollment: 45 participants

Conditions and interventions

Conditions

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

Asciminib Drug
Inotuzumab ozogamicin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2027 (Estimated)
Primary completion: Dec 31, 2030 (Estimated)
Completion: Dec 31, 2030 (Estimated)
Last update posted: Nov 13, 2026

2027 – 2030

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
University of Miami Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Not yet recruiting
University of Chicago Comprehensive Cancer Center	Chicago	Illinois	60805	Not yet recruiting
Columbia University Irving Medical Center	New York	New York	10032	Recruiting
University of Washington Fred Hutchinson Comprehensive Cancer Center	Seattle	Washington	98109	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07936266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 13, 2026 · Synced Nov 14, 2026